Sobetirome

"目录号: HY-14824

Membrane Transporter/Ion ChannelNeuronal Signaling-

ABT 894是nAChR的激动剂，是一种有潜力的非兴奋剂来治疗注意力缺陷症。

nAChR

相关产品

L-Nicotine-PNU-282987-Vinblastine-Carbamoylcholine chloride-PNU-120596-Pancuronium dibromide-Aniracetam-Catharanthine-Varenicline-Hexamethonium Bromide-Vecuronium bromide-GTS-21 dihydrochloride-Tebanicline hydrochloride-A-867744-Adiphenine hydrochloride-

生物活性

Description

ABT 894 is an agonist ofnicotinic acetylcholine receptor (nAChR), used as a potential non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

In Vitro

ABT-894 is more potent than ABT-089 at both receptor subtypes, with Kivalues of 1.9 nM for125I-α-conotoxinMII binding and of 1.3 nM for125I-epibatidine binding[1].

In Vivo

ABT-894 (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs compared to vehicle monkey[1]. ABT-894 (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage[2].

References

[1].Zhang D, et al. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29(4):508-17.

[2].Zhang D, ET AL. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30(14):1901-11.